Nivolumab injection Online | Opdyta cost | Apple pharmaceuticals

DESCRIPTION

Nivolumab is a prescription drug which is used under the supervision of a doctor
Nivolumab belongs to a human monoclonal antibody which stops the interaction between PD-1 and its ligands, PD-L1 and PD-L2.

Nivolumab is an IgG4 kappa immunoglobulin which has a calculated molecular mass of 146 kDa. It is expressed in a recombinant Chinese Hamster Ovary (CHO) cell line.  Nivolumab is also known as an immune checkpoint inhibitor. Sometimes these drugs are called targeted therapies because they target specific proteins (receptors) on the surface of cells.

INDICATION

Nivolumab is indicated for the treatment of patients having :
• Melanoma
• Non-Small Cell Lung Cancer
• Kidney (Renal Cell) Cancer

MECHANISM

Binding of these ligands to the PD-1 receptor occur on T cells, prohibits T cell multiplication and cytokine production. Upregulation of the PD-1 ligands occurs in some tumor and signaling via this pathway can provide to the prohibition of active T-cell immune surveillance of tumor.

Nivolumab belongs to human immunoglobulin G4 (IgG4) monoclonal antibody which binds to the PD-1 receptor and stops its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated prevention of the immune response, containing the anti-tumor immune response, resulting in reduced tumor growth.

DOSAGE


Nivolumab recommended dosage for unresectable or metastatic melanoma: 
As a single agent is either 240mg every 2 weeks or 480mg every 4 weeks given as IV infusion over 30 minutes until disease progression or unacceptable toxicity

With ipilimumab:
The recommended dose of Nivolumab is 1mg/kg administrated as an intravenous infusion over 30 minutes, followed by ipilimumab 3mg/kg given as IV over 90 minutes on the same day. Duration 3 weeks of max 4 doses, after completing combination does continue the single agent treatment

For adjuvant treatment of melanoma:
As a single agent is either 240mg every 2 weeks or 480mg every 4 weeks given as IV infusion over 30 minutes until disease progression or unacceptable toxicity for up to 1 year.

PRECAUTION

Immune-mediated pneumonitis may appear to the patients, hence withhold for moderate and permanently discontinue for serious or life-threatening pneumonitis.

Other clinically important and possible fatal immune-mediated side effects (eg, myocarditis, rhabdomyolysis, myositis, uveitis, iritis, pancreatitis) can appear after therapy discontinuation.

Severe infusion reactions resulted (rare, <1%); discontinue if severe or life-threatening; break or slow rate of infusion in patients with mild or moderate infusion reactions.

DRUG INTERACTION

No formal pharmacokinetic drug interaction studies.

STORAGE

Store at under refrigeration at 2° to 8°.

MISSED DOSE

If you missed a dose take it as soon as possible, if time reach for next dose, then skip the missed dose and continue regular schedule. Avoid taking two doses at a time. Avoid taking a missed dose within 12hrs of the next dose.



FOR MORE INFORMATION

EMAIL:


applepharmaceutical@gmail.com


PHONE:


91- 9987711567


Comments

Post a Comment

Popular posts from this blog

Cabozantinib (Cometriq, Cabometyx) tablet Online | Apple pharmaceuticals

DESCRIPTION Cabozantinib  which is a type of targeted therapy drug used to recover from medullary thyroid cancer and kidney cancer that has spread. Its label contains a black box warning of gastrointestinal perforations, fistulas, and hemorrhage. Cabozantinib is a prescription drug which is used under the supervision of doctors INDICATION Cabozantinib  is used for the treatment of metastatic medullary thyroid cancer and for the treatment of patients having advanced renal cell carcinoma (RCC) who have to get before anti-angiogenic therapy. MECHANISM Cabozantinib   is also called a tyrosine kinase inhibitor (targeted therapy drug). It works by prohibiting the signals inside cancer cells which made them grow and multiply. This may help to block or reduced the growth of cancer. It can also prohibit new blood vessels growing in cancer. Cancer cells require to make new blood vessels so they can develop and spread. DOSAGE MODIFICATION Avoid substitute  Caboz...
Read more

Evertor 10mg tablet - Everolimus | Myapplepharma

Description Evertor belongs to the class of anti-cancer drugs Evertor contains an active compound known as Everolimus which interferes with the development of cancer cell and the process is slowed down. Evertor tablets is not a curable medication, which helps to slow their spreading into the body. Prescribed For The drug Evertor is mainly indicated for the treatment of the following disease • kidney carcinoma • Breast carcinoma • Brain carcinoma Evertor is also used to treat in various advanced stage cancer in stomach, intestines or pancreas. Mechanism Evertor is a prohibition of mTOR, links at peak compatibility to FK506 binding protein 12, through producing drug complex which prevents the productive of mTOR, the main ingredient which is used as everolimus. This inhibition reduces the activity of effectors downstream, which may lead to stoppage of cell progression from G1 into S phase, Finally causes cell growth arrest and apoptosis Dosage regimen of Evertor In...
Read more

Everotas 5mg tablet - Everolimus | Myapplepharma

DESCRIPTION Everotas 5mg belongs to a class of anti-cancer drugs. Everotas 5mg contains an active compound known as Everolimus which interferes with the development of cancer cell and the process is slowed down. Everotas 5mg tablets is not a curable medication, which helps to slow their spreading into the body. PRESCRIBED FOR The drug Everotas 5mg is mainly used for the treatment of the following disease • kidney carcinoma • Breast carcinoma • Brain carcinoma Everotas 5mg is also used to treat in various advanced stage cancer in stomach, intestines or pancreas. CLINICAL PHARMACOLOGY OF EVEROTAS Everolimus is a prohibition of mTOR, links at peak compatibility to FK506 binding protein 12, through producing drug complex which prevents the productive of mTOR. This inhibition reduces the activity of effectors downstream, which may lead to stoppage of cell progression from G1 into S phase, finally causes cell growth arrest and apoptosis. Everotas also prohibits the express...
Read more